David Kang Halozyme Therapeutics

David Kang is Director of Drug Delivery and Innovation at Halozyme Therapeutics. He has been with Halozyme since 2008 and is a subject matter expert in recombinant human hyaluronidase, facilitating rapid, large-volume subcutaneous administration of biotherapeutics. He is also an officer of the Subcutaneous Drug Development and Delivery Consortium and is a member of the Industry Council of the Controlled Release Society. Before Halozyme, David spent over a decade between Pfizer and Schering-Plough researching oncology therapeutics and viral-based gene delivery. He started his research career at the University of California at San Diego, working on gene therapy approaches to infectious diseases, where he also did his undergraduate studies in microbiology and graduate work in virology.